Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

NCT02727335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 318

Last updated 2023-05-24

No results posted yet for this study

Summary

Description of clinical and anatomical features and long-term follow-up for patients with ALK rearrangement and treated by crizotinib

Conditions

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Denis Moro-Sibilot · Intergroupe Francophone de Cancerologie Thoracique

  • Michael Duruisseaux · Intergroupe Francophone de Cancerologie Thoracique

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727335 on ClinicalTrials.gov